Radiochemisty

放射化学和分子成像探针（RMIP）核心设施位于 癌症中心的实验室研究和临床分子成像计划-包括癌症生物学， 医学、化学、物理学、放射化学、药理学和工程学，是世界上最大的 在临床和研究产品的生产数量方面，MSKCC的生产单位。关于RMIP 核心设施的建立是为了向调查人员提供放射性核素， 放射性核素转化为放射性标记的诊断和/或治疗药物， 研究和患者制剂。RMIP核心基金由三个主要部分组成， （a）回旋加速器装置。MSKCC EBCO回旋加速器 第72街生产18F，1241，86 Y和89 Zr，正电子发射放射性核素用于研究和临床 （B）小分子放射化学部分。本节包括回旋加速器产生的 正电子放射性核素转化为放射性化学品和放射性药物;（c）抗体标记 科.本节负责按要求对肽和单克隆抗体进行放射性标记 临床前和临床研究人员用于癌症诊断和治疗目的。MSKCC和 RMIP Core Facility作为影像和医学临床翻译中心享有盛誉， 治疗剂。具体而言，关于放射性药物的翻译，在过去20年中， 多年来，RMIP核心设施已经翻译了37种放射性药物用于研究临床试验（成像和 治疗）在人类中使用放射性标记的抗体、小分子、纳米颗粒和放射治疗剂。到 为了满足不断增长的计划需求和新的联邦法规，MSKCC实施了 在未来五年内对我们的放射化学设施（包括GMP环境）进行重大投资 年RMIP Core提供的服务过去曾支持26名调查人员的研究 年在过去的赠款期间，核心小组的工作为174份研究人员的出版物做出了贡献。 5个研究项目。

The Radiochemistry and Molecular Imaging Probes (RMIP) Core Facility functions at the Intersection of the Cancer Center's laboratory research and clinical molecular Imaging initiatives - including cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology and engineering, and is the largest manufacturing unit at MSKCC in terms of the number of clinical and research products produced. The RMIP Core Facility was established to provide investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations. The RMIP Core Facility consists of three major elements working closely together to provide the following services: (a) The Cyclotron Unit. Our MSKCC EBCO cyclotron on 72nd street produces 18F, 1241, 86Y and 89Zr, positron emitting radionuclides for research and clinical applications; (b) The Small Molecule Radiochemistry Section. This section incorporates cyclotron-produced positron-emitting radionuclides into radiochemicals and radiopharmaceuticals; (c) The Antibody Labeling Section. This section is responsible for the radiolabeling of peptides and monoclonal antibodies as requested by preclinical and clinical investigators for both cancer diagnostic and therapeutic purposes. MSKCC and the RMIP Core Facility have an outstanding reputation as a center for clinical translation of both imaging and therapeutic agents. Specifically, with regard to the translation of radiopharmaceuticals, over the past 20 years, the RMIP Core Facility has translated 37 radiopharmaceuticals for research clinical trials (imaging and therapy) in humans with radiolabeled antibodies, small molecules, nanoparticles and radiotherapeutics. To meet the growing programmatic demands and new federal regulations, MSKCC has implemented a significant investment In our radiochemistry facilities (to include GMP environments) over the next five years. The services provided by the RMIP Core have supported the research of 26 investigators in the past year. During the past grant period the work of the Core has contributed to 174 publications of researchers from 5 research programs.